Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186576
First received: September 14, 2005
Last updated: October 13, 2010
Last verified: October 2010
  Purpose

To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.


Condition Intervention
Myelodysplastic Syndromes
Myeloproliferative Disorders
Blood and Marrow Transplant (BMT)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Disorders (MPD)
Procedure: nonmyeloablative allogeneic hematopoietic cell transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Efficacy of transplant [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: December 2001
Study Completion Date: July 2010
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Detailed Description:

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:- Myelodysplastic Syndromes

  • Myeloproliferative Disorders
  • HLA matched donor available

Exclusion Criteria:- organ dysfunction

  • HIV positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186576

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Ginna Laport Stanford University
  More Information

Publications:
Responsible Party: Ginna Laport, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00186576     History of Changes
Obsolete Identifiers: NCT00052546
Other Study ID Numbers: BMT128, 75826, BMT128
Study First Received: September 14, 2005
Last Updated: October 13, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Disease
Syndrome
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Pathologic Processes

ClinicalTrials.gov processed this record on October 19, 2014